| Clinical data | |
|---|---|
| Other names | N-n-Butyl-N-methyl-11-(3,17β-dihydroxyestra-1,3,5(10)-trien-7α-yl)undecanamide |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C34H55NO3 |
| Molar mass | 525.818 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
ICI-164384, also known asN-n-butyl-N-methyl-11-(3,17β-dihydroxyestra-1,3,5(10)-trien-7α-yl)undecanamide, is asteroidalantiestrogen and asyntheticderivative ofestradiol which is closely related tofulvestrant and was never marketed.[1][2] It is asilent antagonist of theestrogen receptor (ER) with no intrinsicestrogenic activity and hence is a pure antiestrogen, unlikeselective estrogen receptor modulators (SERMs) liketamoxifen.[1][2] The drug was under development byAstraZeneca for the treatment ofbreast cancer but was discontinued in favor offulvestrant,[3] which is very similar to ICI-164384 but is more potent in comparison.[4]
Thisantineoplastic orimmunomodulatorydrug article is astub. You can help Wikipedia byexpanding it. |